EA201591994A1 - CYSTEIN OR ITS DERIVATIVE FOR THE TREATMENT OF ATROPHIC GASTRITIS - Google Patents

CYSTEIN OR ITS DERIVATIVE FOR THE TREATMENT OF ATROPHIC GASTRITIS

Info

Publication number
EA201591994A1
EA201591994A1 EA201591994A EA201591994A EA201591994A1 EA 201591994 A1 EA201591994 A1 EA 201591994A1 EA 201591994 A EA201591994 A EA 201591994A EA 201591994 A EA201591994 A EA 201591994A EA 201591994 A1 EA201591994 A1 EA 201591994A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cysteine
atrophic gastritis
cystein
derivative
treatment
Prior art date
Application number
EA201591994A
Other languages
Russian (ru)
Inventor
Осмо Суованиэми
Original Assignee
Биохит Оий
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биохит Оий filed Critical Биохит Оий
Publication of EA201591994A1 publication Critical patent/EA201591994A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к фармацевтически приемлемой композиции, содержащей цистеин в качестве активного агента, выбранный из L-цистеина, D-цистеина и N-ацетилцистеина, для применения для лечения атрофического гастрита путем введения дозы 300-1500 мг указанного цистеина в сутки в течение по меньшей мере 2 месяцев, или в течение 3 месяцев, или даже 4 месяцев. Настоящее изобретение также относится к способу лечения субъектов, страдающих атрофическим гастритом, включающему введение указанным субъектам композиции согласно изобретению, содержащей цистеин в качестве активного агента, с применением указанной схемы приема.The present invention relates to a pharmaceutically acceptable composition containing cysteine as an active agent, selected from L-cysteine, D-cysteine and N-acetylcysteine, for use in treating atrophic gastritis by administering a dose of 300-1500 mg of said cysteine per day for at least least 2 months, or within 3 months, or even 4 months. The present invention also relates to a method of treating subjects suffering from atrophic gastritis, comprising administering to said subjects a composition according to the invention containing cysteine as an active agent, using said regimen.

EA201591994A 2013-05-13 2014-05-12 CYSTEIN OR ITS DERIVATIVE FOR THE TREATMENT OF ATROPHIC GASTRITIS EA201591994A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20135503A FI20135503L (en) 2013-05-13 2013-05-13 Cysteine or its derivative for the treatment of atrophic gastritis
PCT/FI2014/050351 WO2014184435A1 (en) 2013-05-13 2014-05-12 Cysteine or a derivative thereof for the treatment of atrophic gastritis

Publications (1)

Publication Number Publication Date
EA201591994A1 true EA201591994A1 (en) 2016-05-31

Family

ID=51897812

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591994A EA201591994A1 (en) 2013-05-13 2014-05-12 CYSTEIN OR ITS DERIVATIVE FOR THE TREATMENT OF ATROPHIC GASTRITIS

Country Status (6)

Country Link
EP (1) EP2996687A4 (en)
CN (1) CN105492002A (en)
EA (1) EA201591994A1 (en)
FI (1) FI20135503L (en)
HK (1) HK1223284A1 (en)
WO (1) WO2014184435A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20216361A1 (en) * 2021-12-29 2023-06-30 Biohit Oyj Use of L-cysteine for improving the structure and function of gastric mucosa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI122914B (en) * 2005-04-01 2012-08-31 Biohit Oyj Food composition for binding of acetaldehyde in the mouth and in the digestive tract and process for the preparation of the composition
FI20060501L (en) * 2006-05-22 2007-11-23 Biohit Oyj Composition and method for binding acetaldehyde in the stomach
FI20065542A0 (en) * 2006-09-01 2006-09-01 Biohit Oyj Method and Sampling Kit for Assessment of Abdominal Mucosal Condition
CN102316730A (en) * 2008-05-09 2012-01-11 天雅瑞药业有限公司 Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation
FI20115377A (en) * 2011-04-18 2012-10-19 Biohit Oyj Medical products for use in conditions related to microbial infections of upper respiratory and digestive organs
US20160022620A1 (en) * 2013-03-12 2016-01-28 Biohit Oyj Encapsulated composition for binding aldehydes in the stomach

Also Published As

Publication number Publication date
FI20135503L (en) 2014-11-14
HK1223284A1 (en) 2017-07-28
CN105492002A (en) 2016-04-13
EP2996687A4 (en) 2016-12-07
WO2014184435A1 (en) 2014-11-20
EP2996687A1 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
PH12016502355B1 (en) Pharmaceutical composition
EA201490254A1 (en) COMBINED TREATMENT OF HEPATITIS C
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
EA201500265A1 (en) ANTI-FLY VIRUS REPLICATION INHIBITORS
PE20142314A1 (en) INTRANASAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ712270A (en) Pharmaceutical composition of s-ketamine hydrochloride
EA201590371A1 (en) 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS
MX2021008610A (en) Cancer treatment using combinations of erk and raf inhibitors.
EA201690223A1 (en) FACTOR INHIBITORS IN THE COMPLEMENT BASED ON PIPERIDININILINDOL DERIVATIVES AND THEIR APPLICATION
EA201490377A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKVINIMODE AND GLATIRAMER ACETATE
WO2013022846A3 (en) Flavonoid compounds
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA202090683A2 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
FI129157B (en) Composition for use in reducing the incidence of or preventing severe headaches
EA201591507A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY LACHINIMODOM
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
AR092691A1 (en) PHARMACEUTICAL COMPOSITION THAT REBAMIPIDA INCLUDES
EA201490573A1 (en) CONTAINING BENZOTHIAZOLONE
EA201591180A1 (en) COMPOSITIONS OF THE LFA-1 INHIBITOR
EA201591994A1 (en) CYSTEIN OR ITS DERIVATIVE FOR THE TREATMENT OF ATROPHIC GASTRITIS
UA109944U (en) PHARMACEUTICAL COMPOSITION TO REDUCE THE N-OXIDE OF TRIMETHYLAMINE LEVEL
EA201500368A1 (en) PHARMACEUTICAL COMPOSITION OF 1-ADAMANTYLETHYLOXY-3-MORFOLIN-2-PROPANOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR TREATING CARDIOVASCULAR PATHOLOGY
MX2014006990A (en) Treatment of type i and type ii diabetes.